These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36100115)

  • 1. Molecular alterations in anti-apoptotic BCL2 family proteins in breast cancer cell line models, drug sensitivities and dependencies to guide the development of BCL2 inhibitors.
    Voutsadakis IA
    Gene; 2022 Dec; 847():146881. PubMed ID: 36100115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer sub-types display heterogeneity in gene amplification and mRNA expression of the anti-apoptotic members of BCL2 family.
    Voutsadakis IA
    Gene; 2023 Mar; 857():147179. PubMed ID: 36627096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression Ratios of the Antiapoptotic BCL2 Family Members Dictate the Selective Addiction of Kaposi's Sarcoma-Associated Herpesvirus-Transformed Primary Effusion Lymphoma Cell Lines to MCL1.
    Dunham D; Viswanathan P; Gill J; Manzano M
    J Virol; 2022 Dec; 96(23):e0136022. PubMed ID: 36416587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in
    Nangia V; Siddiqui FM; Caenepeel S; Timonina D; Bilton SJ; Phan N; Gomez-Caraballo M; Archibald HL; Li C; Fraser C; Rigas D; Vajda K; Ferris LA; Lanuti M; Wright CD; Raskin KA; Cahill DP; Shin JH; Keyes C; Sequist LV; Piotrowska Z; Farago AF; Azzoli CG; Gainor JF; Sarosiek KA; Brown SP; Coxon A; Benes CH; Hughes PE; Hata AN
    Cancer Discov; 2018 Dec; 8(12):1598-1613. PubMed ID: 30254092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment.
    Gomez-Bougie P; Maiga S; Tessoulin B; Bourcier J; Bonnet A; Rodriguez MS; Le Gouill S; Touzeau C; Moreau P; Pellat-Deceunynck C; Amiot M
    Blood; 2018 Dec; 132(25):2656-2669. PubMed ID: 30309889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis.
    Arai S; Jonas O; Whitman MA; Corey E; Balk SP; Chen S
    Clin Cancer Res; 2018 Nov; 24(21):5458-5470. PubMed ID: 30021909
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibition of MCL1 induces apoptosis in anaplastic large cell lymphoma and in primary effusion lymphoma.
    Quentmeier H; Geffers R; Hauer V; Nagel S; Pommerenke C; Uphoff CC; Zaborski M; Drexler HG
    Sci Rep; 2022 Jan; 12(1):1085. PubMed ID: 35058488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.
    Seiller C; Maiga S; Touzeau C; Bellanger C; Kervoëlen C; Descamps G; Maillet L; Moreau P; Pellat-Deceunynck C; Gomez-Bougie P; Amiot M
    Cell Death Dis; 2020 May; 11(5):316. PubMed ID: 32371863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venetoclax-Resistant T-ALL Cells Display Distinct Cancer Stem Cell Signatures and Enrichment of Cytokine Signaling.
    Shah K; Al Ashiri L; Nasimian A; Ahmed M; Kazi JU
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Confounding off-target effects of BH3 mimetics at commonly used concentrations: MIM1, UMI-77, and A-1210477.
    Mallick DJ; Soderquist RS; Bates D; Eastman A
    Cell Death Dis; 2019 Feb; 10(3):185. PubMed ID: 30796196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma.
    Tseng HY; Dreyer J; Emran AA; Gunatilake D; Pirozyan M; Cullinane C; Dutton-Regester K; Rizos H; Hayward NK; McArthur G; Hersey P; Tiffen J; Gallagher S
    Int J Cancer; 2020 Oct; 147(8):2176-2189. PubMed ID: 32249419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.
    Williams MM; Lee L; Hicks DJ; Joly MM; Elion D; Rahman B; McKernan C; Sanchez V; Balko JM; Stricker T; Estrada MV; Cook RS
    Mol Cancer Res; 2017 Mar; 15(3):259-268. PubMed ID: 28039357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells.
    Inoue C; Sobue S; Kawamoto Y; Nishizawa Y; Ichihara M; Abe A; Hayakawa F; Suzuki M; Nozawa Y; Murate T
    Biochem Biophys Res Commun; 2020 May; 525(4):1074-1080. PubMed ID: 32184020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding MCL1: from cellular function and regulation to pharmacological inhibition.
    Sancho M; Leiva D; Lucendo E; Orzáez M
    FEBS J; 2022 Oct; 289(20):6209-6234. PubMed ID: 34310025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma.
    Jacob M; Wiedemann S; Brücher D; Pieper NM; Birkhold M; Särchen V; Jeroch J; Demes MC; Gretser S; Braun Y; Gradhand E; Rothweiler F; Michaelis M; Cinatl J; Vogler M
    Br J Cancer; 2023 Nov; 129(10):1667-1678. PubMed ID: 37723317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.
    Li L; Pongtornpipat P; Tiutan T; Kendrick SL; Park S; Persky DO; Rimsza LM; Puvvada SD; Schatz JH
    Leukemia; 2015 Aug; 29(8):1702-12. PubMed ID: 25882699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCL2L1 inhibitor A-1331852 inhibits MCL1 transcription and triggers apoptosis in acute myeloid leukemia cells.
    Chiou JT; Wu YY; Lee YC; Chang LS
    Biochem Pharmacol; 2023 Sep; 215():115738. PubMed ID: 37562509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCL2 and MCL1 inhibitors for hematologic malignancies.
    Roberts AW; Wei AH; Huang DCS
    Blood; 2021 Sep; 138(13):1120-1136. PubMed ID: 34320168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.
    Paulus A; Chitta K; Akhtar S; Personett D; Miller KC; Thompson KJ; Carr J; Kumar S; Roy V; Ansell SM; Mikhael JR; Dispenzieri A; Reeder CB; Rivera CE; Foran J; Chanan-Khan A
    Br J Haematol; 2014 Feb; 164(3):352-365. PubMed ID: 24236538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide.
    Pilling AB; Hwang C
    Prostate; 2019 Aug; 79(11):1347-1359. PubMed ID: 31228231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.